These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 19389498)

  • 61. Stem-cell transplantation for multiple myeloma in the era of novel drugs.
    Bensinger W
    J Clin Oncol; 2008 Jan; 26(3):480-92. PubMed ID: 18056678
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma.
    Habermann TM; Lossos IS; Justice G; Vose JM; Wiernik PH; McBride K; Wride K; Ervin-Haynes A; Takeshita K; Pietronigro D; Zeldis JB; Tuscano JM
    Br J Haematol; 2009 May; 145(3):344-9. PubMed ID: 19245430
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Melphalan and its role in the management of patients with multiple myeloma.
    Falco P; Bringhen S; Avonto I; Gay F; Morabito F; Boccadoro M; Palumbo A
    Expert Rev Anticancer Ther; 2007 Jul; 7(7):945-57. PubMed ID: 17627453
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Thalidomide: present and future in multiple myeloma.
    Hussein MA
    Expert Rev Anticancer Ther; 2005 Feb; 5(1):25-31. PubMed ID: 15757435
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Frontline treatment of multiple myeloma in elderly patients.
    Moreau P; Hulin C; Facon T
    Blood Rev; 2008 Nov; 22(6):303-9. PubMed ID: 18550234
    [TBL] [Abstract][Full Text] [Related]  

  • 66. [The treatment of relapsed or refractory multiple myeloma].
    Tsurumi H
    Nihon Rinsho; 2015 Jan; 73(1):114-8. PubMed ID: 25626315
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Lenalidomide for the treatment of B-cell malignancies.
    Chanan-Khan AA; Cheson BD
    J Clin Oncol; 2008 Mar; 26(9):1544-52. PubMed ID: 18285605
    [TBL] [Abstract][Full Text] [Related]  

  • 68. An update: health economics of managing multiple myeloma.
    Moeremans K; Annemans L
    Eur J Cancer; 2006 Jul; 42(11):1684-91. PubMed ID: 16781867
    [TBL] [Abstract][Full Text] [Related]  

  • 69. [Clinical implications of bortezomib in frontline treatment of newly-diagnosed multiple myeloma].
    Ohashi K
    Gan To Kagaku Ryoho; 2008 Jun; 35(6):1029-32. PubMed ID: 18633240
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Complete remission upon bortezomib-dexamethasone therapy in three heavily pretreated multiple myeloma patients relapsing after allogeneic stem cell transplantation.
    Tosi P; Zamagni E; Cangini D; Tacchetti P; Perrone G; Ceccolini M; Baccarani M; Cavo M
    Ann Hematol; 2006 Aug; 85(8):549-51. PubMed ID: 16614846
    [No Abstract]   [Full Text] [Related]  

  • 71. Role of autologous stem-cell transplantation in multiple myeloma.
    Attal M; Harousseau JL
    Best Pract Res Clin Haematol; 2007 Dec; 20(4):747-59. PubMed ID: 18070717
    [TBL] [Abstract][Full Text] [Related]  

  • 72. [Very good partial response and long time to progression by short-term bortezomib plus dexamethasone therapy for a patient with relapsed and refractory multiple myeloma-a case report].
    Fukushima T; Iwao H; Nakajima A; Miki M; Sakai T; Sawaki T; Tanaka M; Masaki Y; Hirose Y; Umehara H
    Gan To Kagaku Ryoho; 2009 Aug; 36(8):1387-9. PubMed ID: 19692786
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Recent trends in the management of newly diagnosed multiple myeloma.
    Reece DE
    Curr Opin Hematol; 2009 Jul; 16(4):306-12. PubMed ID: 19491669
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Salvage therapy in Hodgkin's lymphoma.
    Mendler JH; Friedberg JW
    Oncologist; 2009 Apr; 14(4):425-32. PubMed ID: 19342476
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Monotherapy with low-dose thalidomide for relapsed or refractory multiple myeloma: better response rate with earlier treatment.
    Maisnar V; Radocha J; Büchler T; Bláha V; Malý J; Hájek R
    Eur J Haematol; 2007 Oct; 79(4):305-9. PubMed ID: 17803678
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Autologous stem cell transplantation in the elderly including pre- and post-treatment options.
    Kumar SK; Hayman SR; Kyle RA
    Bone Marrow Transplant; 2007 Dec; 40(12):1115-21. PubMed ID: 17680019
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Lenalidomide in combination with dexamethasone for the treatment of multiple myeloma after one prior therapy.
    Hazarika M; Rock E; Williams G; Dagher R; Sridhara R; Booth B; Farrell A; Justice R; Pazdur R
    Oncologist; 2008 Oct; 13(10):1120-7. PubMed ID: 18922829
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Targeted treatments to improve stem cell outcome: old and new drugs.
    Raab MS; Breitkreutz I; Anderson KC
    Bone Marrow Transplant; 2007 Dec; 40(12):1129-37. PubMed ID: 17768392
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Proteasome inhibition for treatment of multiple myeloma: clinical update.
    Stadtmauer EA
    J Natl Compr Canc Netw; 2004 Nov; 2 Suppl 4():S10-5. PubMed ID: 19795531
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Clinical and immunohistochemical features associated with a response to bortezomib in patients with multiple myeloma.
    Dawson MA; Opat SS; Taouk Y; Donovan M; Zammit M; Monaghan K; Horvath N; Roberts AW; Prince HM; Hertzberg M; McLean CA; Spencer A
    Clin Cancer Res; 2009 Jan; 15(2):714-22. PubMed ID: 19147779
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.